WD-890 in adults with moderate to severe plaque psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of WD-890 in adults with moderate to severe plaque psoriasis. Participants are assigned to receive either WD-890 or placebo to determine improvement in psoriasis symptoms and safety. Key eligibility includes adults 18–75 with diagnosed plaque psoriasis, at least 10% body surface area affected, PASI ≥12, and sPGA ≥3. Major exclusion criteria include nonplaque psoriasis forms, uncontrolled hypertension, and advanced heart failure. The study is led by Zhejiang Wenda Pharma Technology LTD. and conducted at the Hospital of Dermatology, Chinese Academy of Medical Sciences in Nanjing, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female participant aged 18 to 75 years(inclusive)at the time of informed consent.
* Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.
* Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization

Exclusion Criteria:

* Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)
* Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted
* Class III or IV congestive heart failure by New York Heart Association Criteria

Where it's running

• Hospital of Dermatology, Chinese Academy of Medical Sciences
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Lu Qianjin
• Email: qianlu5860@gmail.com
• Phone: +8613787097676

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HS-20137: a treatment option for adults with moderate-to-severe plaque psoriasis

  A phase 2 open-label study tests HS-20137 given as 200 mg at weeks 0, 4 and 8 to see if it is safe and helps patients with moderate-to-severe plaque psoriasis.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Beijing, Beijng · NCT07879885

• TYK2 inhibitor for adults with moderate to severe plaque psoriasis

  This will test whether a TYK2 inhibitor taken for 12 weeks helps adults with moderate to severe plaque psoriasis improve their skin and symptoms.

  Recruiting Usynova Pharmaceuticals Ltd. · Shanghai · NCT07234591

• Assessing Bimekizumab Levels in Breast Milk of Nursing Mothers

  This study tests how much of the medication bimekizumab is found in the breast milk of mothers who have been using it for at least 12 weeks after giving birth to see if it's safe for their babies.

  Recruiting at 14 sites Phase 1 UCB Pharma · Santa Monica, California and 13 other locations · NCT06888193

• Evaluating the effects of vunakizumab on moderate-to-severe plaque psoriasis

  This study is testing if a new medication called vunakizumab can help people with moderate-to-severe plaque psoriasis feel better and improve their quality of life over a year.

  Recruiting First Hospital of China Medical University · Shenyang, Liaoning · NCT06696417

• Evaluating the safety and effectiveness of Sotyktu for plaque psoriasis in Korea

  This study is testing if a new medication called Sotyktu is safe and effective for adults in Korea with moderate-to-severe plaque psoriasis who need treatment.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06258668

• Ponesimod in adults with moderate-to-severe chronic plaque psoriasis

  This study tests whether ponesimod is safe and helps clear moderate-to-severe plaque psoriasis in adults aged 18–65.

  Recruiting at 10 sites Phase 3 Vanda Pharmaceuticals · Glendale, Arizona and 9 other locations · NCT07362017

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.